Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model

Journal of Pharmaceutical Sciences

Volumn 87, Issue 7, 1998, Pages 886-890

  Hu, Ming ^a   Roland, Kyndra ^a   Ge, Lanbo ^a   Chen, Jiyue ^a   Li, Yiqi ^a   Tyle, Praveen ^b   Roy, Samir ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; HYPOXANTHINE DERIVATIVE; NOLATREXED; THYMIDYLATE SYNTHASE INHIBITOR; XANTHINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETERMINATION; DRUG PENETRATION; DRUG STABILITY; ENZYME INHIBITION; INTESTINE PERFUSION; MALE; NONHUMAN; RAT; TISSUE DISTRIBUTION;

EID: 0031849072     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970251e     Document Type: Article

References (17)

1. Webber, S.; Bartlett, C. A.; Boritzki, T. J.; Hilliard, J. A.; Howland, E. F.; Johnston, A. L.; Kosa, M.; Margosiak, S. A.; Morse, C. A.; Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol. 1996, 37 (6), p 509-17.
2. Clendeninn, N. J.; Johnston, A. Phase II trials of Thymitag (AG337) in six solid tumor diseases. Proc. Am. Assoc. Cancer Res. 1996, 37, 86 (Abstract #296).
3. Rafi, I.; Boddy, A. V.; Talor, G. A.; Calvete, J. A.; Bailey, N. B.; Lind, M. J.; Newell, D. R.; Calvert, A. H.; Johnston, A.; Clendeninn, N. J. A phase I clinical study of the novel antifolate AG337 given by 5 day oral administration. Proc. Am. Assoc. Cancer Res. 1996, 37, 86 (Abstract #293).
4. Hu, M.; Sinko, P. J.; deMeere, A. L. J.; Johnson, D. A.; Amidon, G. L. Membrane permeability parameters for some amino acids and β-lactam antibiotics: Application of boundary layer approach. J. Theor. Biol. 1988, 131, 107-114.
5. Zheng, L.; Chen, J.; Zhu, Y.; Yang, H.; Elmquist, W.; Hu, M. Comparison of L-and D-methionine transport in a cultured intestinal epithelial model and a perfused rat intestinal model. Pharm. Res. 1994, 11, 1771-1776.
6. Amidon, G. L.; Sinko, P. J.; Fleisher, D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 1988, 5, 651-654.
7. Plagemann, P. G. W.; Wohlhueter, R. M. Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells. Curr. Top. Membr. Transport 1980, 14, 225-330.
8. Plagemann, P. G. W.; Wohlhueter, R. M.; Clive Woffendin, Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta 1988, 947, 405-443.
9. Adibi, S. A.; Morse, E. L. Intestinal transport of dipeptides in man: relative importance of hydrolysis and absorption. J. Clin. Invest. 1971, 50, 2266-2275.
10. Krag, E.; Philips, S. F. Active and passive bile acid absorption in man. Perfusion studies of the ileum and jejunum. J. Clin. Invest. 1974, 53, 1686-1694.
11. Munck, B. G. Intestinal absorption of amino acids, In Physiology of Gastrointestinal Tract; Johnson, L. R., Ed.; Raven Press: New York, 1981; pp 1097-1022.
12. Riley, S. A.; Warhurst, G.; Crowe, P. T.; Turnberg, L. A. Active hexose transport across cultured human Caco-2 cells: characterization and influence of culture conditions. Biochim. Biophys. Acta, 1991, 1066, 175-182.
13. +-coupled carriers at both apical and basolateral membranes. J. Biol. Chem. 1993, 268, 7640-42.
14. Hidalgo, I. J.; Ryan, F. M.; Marks, G. J.; Smith, P. L. pH-dependent transepithelial transport of cephalexin in rabbit intestinal mucosa. Int. J. Pharm. 1993, 98, 83-92.
15. Hu, M.; Borchardt, R. T. Mechanism of L-α-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm. Res. 1990, 7, 1313-1319.
16. Hu, M. Comparison of Uptake Characteristics of Thymidine and Zidovudine in a Human Intestinal Epithelial Model System. J. Pharm. Sci. 1993, 82, 829-833.
17. Osses, N.; Pearson, J. D.; Yudilevich, D. L.; Javis, S. M. Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter. Biochem. J. 1996, 843-848.